rhIL-11辅助紫杉醇联合顺铂治疗晚期NSCLC的效果研究  

Effect of rhIL-11 Assisted Paclitaxel Plus Cisplatin in the Treatment of Advanced NSCLC

作　　者：亢静怡 亢崇照[1] KANG Jingyi;KANG Chongzhao(Department of Oncology,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471003,Henan,China)

机构地区：[1]河南科技大学第一附属医院肿瘤内科,河南洛阳471003

出　　处：《中国药物滥用防治杂志》2023年第5期835-838,共4页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探讨重组人白细胞介素-11(rhIL-11)辅助紫杉醇联合顺铂治疗晚期非小细胞肺癌(NSCLC)的效果.方法:选取2019年12月—2020年12月我院确诊的120例晚期NSCLC患者,采用随机数字表法分为观察组60例(采用rhIL-11辅助紫杉醇联合顺铂治疗),对照组60例(采用紫杉醇联合顺铂治疗).比较两组治疗后近期缓解率、血清肿瘤标志物水平、不良反应发生情况及治疗后1年生存率.结果:观察组治疗近期缓解率为50.00%,高于对照组的26.66%(P<0.05);观察组治疗后血清癌胚抗原(CEA)、细胞角蛋白19(CYFRA21-1)和鳞状上皮细胞癌抗原(SCC)水平与对照组比较,差异无统计学意义(P>0.05);观察组治疗期间贫血、粒细胞减少及血小板减少发生率低于对照组(P<0.05);观察组治疗后1年总生存率与对照组比较,差异无统计学意义(P>0.05).结论:rhIL-11辅助紫杉醇联合顺铂治疗可提高晚期NSCLC患者的近期疗效,降低不良反应发生概率,但对血清肿瘤标志物水平及治疗后1年总生存率无明显影响.Objective:To investigate the effect of recombinant human interleukin-11(rhIL-11)combined with paclitaxel and cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:A total of 120 patients with advanced NSCLC confirmed in the hospital were enrolled between December 2019 and December 2020.According to random number table method,they were divided into observation group(60 cases,rhIL-1lassisted paclitaxel+cisplatin)and control group(60 cases,paclitaxel+cisplatin).The short-term remission rate,serum tumor markers,adverse reactions and 1-year survival rate after treatment were compared between the two groups.Results:The short-term remission rate of the observation group was 50.00%,which was higher than 26.66%of the control group(P<0.05).There was no significant difference in serum carcinoembryonic antigen(CEA),cytokeratin 19(CYFRA21-1)and squamous cell carcinoma antigen(SCC)levels between the observation group and the control group after treatment(P>0.05).The incidence of anemia,granulocytopenia and thrombocytopenia in the observation group during treatment was lower than that in the control group(P<0.05).There was no significant difference in 1-year overall survival rate between the observation group and the control group(P>0.05).Conclusion:rhIL-11 combined with paclitaxel and cisplatin can improve the short-term efficacy of patients with advanced NSCLC and reduce the incidence of adverse reactions,but has no significant effect on serum tumor markers and 1-year overall survival rate after treatment.

关 键 词：重组人白细胞介素-11 紫杉醇 顺铂 非小细胞肺癌 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]